Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biomarin Pharmaceutical's Enterprise Value is $10,257 Mil.
Biomarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was $554 Mil. Therefore, Biomarin Pharmaceutical's EV-to-EBIT ratio for today is 18.51.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Biomarin Pharmaceutical's Enterprise Value
For the Biotechnology subindustry, Biomarin Pharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's Enterprise Value falls into.
Biomarin Pharmaceutical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Biomarin Pharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical (NAS:BMRN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Biomarin Pharmaceutical's current Enterprise Value is $10,257 Mil.
Biomarin Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $554 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Biomarin Pharmaceutical's EV-to-EBITDA for today is:
Biomarin Pharmaceutical's current Enterprise Value is $10,257 Mil.
Biomarin Pharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $651 Mil.
Biomarin Pharmaceutical's current Enterprise Value is $10,257 Mil.
Biomarin Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2,854 Mil.
Biomarin Pharmaceutical's current Enterprise Value is $10,257 Mil.
Biomarin Pharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $475 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomarin Pharmaceutical Enterprise Value Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 